Senator Peter Welch Backs Trump’s Most-Favored-Nation Drug Pricing Plan, Calls for Bipartisan Action

Sen. Peter Welch (D-Vt.) announced on Wednesday that he would support President Donald Trump’s proposal to implement a most-favored-nation drug pricing policy. Welch made the statement during the Axios Future of Health summit, signaling potential bipartisan momentum for the plan.

Welch’s endorsement comes as 70% of Americans express concerns about their ability to afford prescription drugs, according to recent surveys. The president’s policy aims to align U.S. drug prices with those paid by other developed nations, reducing costs for American consumers.

Senator Welch’s Full Commitment to the Plan

During the summit, Axios’ Peter Sullivan asked Welch directly if he would vote in favor of Trump’s proposal. Welch responded:

"I would not only vote for it, I would work actively and aggressively to make it happen."

Welch also urged Trump to move beyond rhetoric, stating:

"He needs to do it, not just talk about it."

Currently, Trump has not introduced formal legislation for the policy, leaving details of implementation unclear.

Bipartisan Efforts to Lower Drug Prices

Welch is collaborating with Sen. Josh Hawley (R-Mo.) on a bipartisan bill that would prohibit drugmakers from charging Americans more than the international average price. The bill, unveiled in early May, serves as a potential Congressional template for Trump’s most-favored-nation approach.

Criticism and Concerns Surrounding the Policy

While Trump has struck deals with at least 16 pharmaceutical companies to lower drug costs, the specifics of these agreements remain undisclosed. Some Democrats argue that the lack of transparency could allow pharmaceutical companies to benefit more than American patients.

The intrigue deepens as lawmakers debate the effectiveness and fairness of the policy, with rural healthcare access emerging as another critical issue in the conversation.